Physician profile
Gregory D Cox
NPI 1891732541
$4,321.20
in general payments reported to CMS, 2019-2025
26 companies · $23.24 in 2025
The $23.24 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,167 · 2020: $686 · 2021: $964 · 2022: $866 · 2023: $615 · 2025: $23.24.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $638.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $638.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $926.21 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $822.87 | 2019-2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $327.57 | 2019-2022 | |
| Amgen INC. | $324.60 | 2019-2023 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $322.02 | 2019-2023 | Jardiance |
| Pfizer INC. | $260.58 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $193.15 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $150.85 | 2019-2023 | Eliquis, Camzyos |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $99.97 | 2019-2023 | Lifevest |
| Boston Scientific Corporation | $97.17 | 2022 | |
| Merck Sharp & Dohme LLC | $96.18 | 2021-2023 | Verquvo |
| Amarin Pharma, INC. | $86.87 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $76.71 | 2020-2023 | Uptravi, Opsumit |
| Novo Nordisk INC | $76.30 | 2019-2021 | |
| Esperion Therapeutics, INC. | $72.93 | 2021-2023 | Nexletol |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tactile Systems Technology INC | $59.45 | 2022 | |
| Astellas Pharma US INC | $55.19 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $53.60 | 2019-2025 | Dupixent |
| Abbott Laboratories | $46.65 | 2021 | |
| Impulse Dynamics (USA) INC. | $43.31 | 2023 | Optimizer |
| Medtronic Vascular, INC. | $36.10 | 2019 | |
| Kestra Medical Technology Services, INC. | $33.27 | 2023 | Assure Wcd |
| Scpharmaceuticals INC. | $20.82 | 2023 | |
| Glaxosmithkline, LLC. | $13.41 | 2019 | |
| Allergan, INC. | $13.23 | 2019 | |
| Medtronic, INC. | $12.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Cox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.